Drug Overview

Smoothened antagonist BMS 833923 is an experimental cancer medicine designed to block a specific growth signal inside cells. It is a highly specialized molecule that targets the foundation of how certain tumors grow and survive. Because it focuses on a very specific protein target, it is considered a Targeted Therapy and a Smart Drug.

This medication is currently being studied in international clinical trials. It is not available for general purchase at a local pharmacy and is only accessible to patients who are part of an approved medical research study.

• Generic name: Smoothened antagonist BMS 833923 (also known as XL139)
• US Brand names: None (Investigational drug)
• Drug Class: Hedgehog signaling pathway inhibitor; Smoothened (SMO) antagonist
• Route of Administration: Oral (taken by mouth as a capsule)
• FDA Approval Status: Investigational (Not currently approved by the FDA for standard medical use)

What Is It and How Does It Work? (Mechanism of Action)

BMS 833923 works by “turning off” a specific communication line inside cells called the Hedgehog signaling pathway. In a healthy developing embryo, this pathway is very important for organizing how organs grow. However, in adults, this pathway should mostly be “quiet.” In some types of cancer, this pathway gets stuck in the “on” position, telling cells to multiply without stopping.

At the molecular level, the process involves three main players: a protein called Sonic Hedgehog, a “gatekeeper” called Patched, and a “switch” called Smoothened (SMO).

When the Hedgehog signal is active, the Smoothened switch moves to the surface of the cell and sends messages deep into the cell nucleus. These messages activate GLI transcription factors, which act like a “print” command for the cell to create more cancer cells and build protective tissue around the tumor.

BMS 833923 works as an antagonist, which means it acts like a physical block or “plug.” It binds directly to the Smoothened protein and prevents it from moving or sending signals. By “locking” the Smoothened switch in the off position, the drug stops the GLI signals. This prevents the tumor from growing, blocks its ability to repair itself, and can lead to the death of the cancer cells.

FDA-Approved  Clinical Indications

Because BMS 833923 is an investigational drug, it does not currently have official FDA-approved uses for the general public. It is being studied in clinical trials for:

Oncological uses

• Investigational treatment for Basal Cell Carcinoma (a type of skin cancer).
• Investigational treatment for metastatic Pancreatic Cancer (often in combination with chemotherapy).
• Investigational research for Small Cell Lung Cancer and Multiple Myeloma.
• Investigational treatment for advanced Solid Tumors that have a specific Hedgehog pathway mutation.

Non-oncological

• None at this time.

Dosage and Administration Protocols

In clinical research settings, BMS 833923 is taken as an oral capsule. The dosage is determined by the specific rules of the research study.

Dose Adjustments

Because the liver processes this medication, doctors monitor liver function blood tests before every treatment cycle. If liver enzymes rise significantly, the dose is typically lowered or paused. There are no established dose starting rules for patients with renal (kidney) insufficiency, but kidney health is tracked during the trial.

Clinical Efficacy and Research Results

Clinical research data from the 2020 to 2025 period have focused on how BMS 833923 performs when combined with standard chemotherapy, especially for difficult cancers like pancreatic cancer.

Numerical data from Phase 1 and Phase 2 trials show that the drug is active in the human body and can successfully lower the “Hedgehog signature” in tumor biopsies. In studies for advanced pancreatic cancer, adding BMS 833923 to standard chemotherapy (gemcitabine) was found to be safe. While some trials showed that it did not significantly improve the overall survival rate for every patient compared to chemotherapy alone, a specific group of patients with high Hedgehog activity appeared to have a better “Disease Control Rate.” Current research is focusing on using numerical data to find the best “biomarkers”—specific genetic signs—to identify which patients will benefit the most.

Safety Profile and Side Effects

BMS 833923 has a safety profile that is very specific to drugs that block the Hedgehog pathway.

Black Box Warning

There is no official FDA Black Box Warning for BMS 833923 because it is an investigational drug.

Common side effects

These occur in more than 10 percent of patients:

• Changes in taste (dysgeusia) or total loss of taste
• Muscle cramps or spasms
• Hair loss (alopecia)
• Feeling very tired (fatigue)
• Nausea and decreased appetite
• Weight loss

Serious adverse events

• Significant increases in liver enzymes (indicating liver stress)
• Severe muscle pain or breakdown (rhabdomyolysis)
• Potential for birth defects (this is a major risk for Hedgehog inhibitors)
• Decreases in blood cell counts

Management strategies

To manage taste changes and weight loss, patients are often referred to a nutritionist. Muscle cramps are sometimes managed with magnesium supplements or gentle stretching. Because this drug can cause severe birth defects, both men and women must use highly effective birth control during treatment and for several months after stopping.

Connection to Stem Cell and Regenerative Medicine

BMS 833923 is a major focus in Research Areas involving stem cell therapy. The Hedgehog pathway is essential for the survival of “cancer stem cells.” These are the stubborn “seed” cells that often survive chemotherapy and cause the cancer to come back years later. Researchers are studying whether blocking Smoothened with BMS 833923 can destroy these cancer stem cells to provide a permanent cure. Additionally, there is interest in the field of regenerative medicine regarding how this drug might affect the body’s natural healing processes, as the Hedgehog pathway is involved in tissue repair.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Comprehensive metabolic panel to check baseline liver and kidney function.
• Complete blood count (CBC) to check red and white blood cells.
• Pregnancy test for women of childbearing age (mandatory).
• Baseline assessment of muscle pain and taste function.

Precautions during treatment

Patients should be aware that taste changes are very common and can affect their desire to eat. It is vital to monitor weight weekly. Because of the risk to a developing baby, patients must follow strict pregnancy prevention protocols provided by the clinical trial site.

Do’s and Don’ts list

• Do take your capsule at the same time every day with a full glass of water.
• Do report any new or severe muscle pain to your care team immediately.
• Do use two forms of effective birth control if you are of childbearing potential.
• Don’t take any new herbal supplements or over-the-counter vitamins without asking your trial doctor first.
• Don’t ignore significant weight loss; talk to your doctor about high-calorie meal plans.
• Don’t donate blood or sperm during treatment or for a specific time after the study ends.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. BMS 833923 is an investigational medication and is not approved by the Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional or your clinical trial oncologist before making any decisions regarding your medical treatment, managing side effects, or participating in a clinical research study.